Table 4.
Protocol | pH | Pco2 (mm Hg) | Po2 (mm Hg) | Base excess (mEq/L) |
---|---|---|---|---|
21% Res | 7.34 ± 0.03 | 42 ± 4 | 36 ± 5 | −4 ± 1 |
50% Res | 7.31 ± 0.02 | 45 ± 3 | 46 ± 7 | −4 ± 1 |
100% Res | 7.37 ± 0.02† | 40 ± 2 | 42 ± 5 | −3 ± 1 |
| ||||
Protocol | Baseline PVR immediately prior to infusion of U46619 | PVR during U46619 0.5μg/kg/min | % Change in PVR from baseline (0.5 μg/kg/min) | |
| ||||
21% Res | 0.31 ± 0.03 | 0.72 ± 0.2‡ | 258 ± 70 | |
50% Res | 0.28 ± 0.05 | 0.6 ± 0.2‡ | 275 ± 54 | |
100% Res | 0.22 ± 0.02* | 0.75 ± 0.2‡ | 321 ± 81 | |
| ||||
Protocol | PVR during U46619 1 μg/kg/min | % Change in PVR from baseline (1 μg/kg/min) | Increase in PAP with U46619 at 1 μg/kg/min (mm Hg) | |
| ||||
21% Res | 1.07 ± 0.25‡ | 343 ± 77 | 35 ± 5 | |
50% Res | 1.03 ± 0.4‡ | 401 ± 121 | 36 ± 3 | |
100% Res | 1.12 ± 0.3‡ | 496 ± 112 | 36 ± 3 |
p < 0.05 compared with 21% Res.
p < 0.05 compared with 50% Res.
p < 0.01 compared with baseline PVR in the same group.